<DOC>
	<DOCNO>NCT02168361</DOCNO>
	<brief_summary>Randomized trial Hepatitis C-genotype 1-infected patient compensate cirrhosis compare standard care ( Peginterferon/Ribavirin/Sofosbuvir ) versus off-label combination simeprevir+ sofosbuvir without Ribavirin .</brief_summary>
	<brief_title>The SIM-SOF Trial Hepatitis C</brief_title>
	<detailed_description>Patients treatment naive prior null response Peg/RBV , must genotype subtype 1a . Must Child 's Class A cirrhosis/compensated history decompensation</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>chronic hepatitis c , cirrhosis biopsyproven , via fibrotest , CPT score less 7 , genotype 1a , INR 2.3 less , serum albumin great 2.7 gm/dL , total bilirubin le 3 gm/dL , platelet count 50,000 per cubic milliliter GFR &gt; 50 ml/min non genotype 1a , history CPT class B C decompensation history , HIV HBV coinfection , prior treatment boceprevir , telaprevir direct act antiviral agent , uncontrolled psychiatric cardiopulmonary disorder , plan pregnancy unwilling/unable practice contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cirrhosis</keyword>
</DOC>